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ABSTRACT
Introduction: Postoperative delirium is one of the most
common complications of major surgery, affecting 10–
70% of surgical patients 60 years and older. Delirium is
an acute change in cognition that manifests as poor
attention and illogical thinking and is associated with
longer intensive care unit (ICU) and hospital stay, long-
lasting cognitive deterioration and increased mortality.
Ketamine has been used as an anaesthetic drug for over
50 years and has an established safety record. Recent
research suggests that, in addition to preventing acute
postoperative pain, a subanaesthetic dose of
intraoperative ketamine could decrease the incidence of
postoperative delirium as well as other neurological and
psychiatric outcomes. However, these proposed benefits
of ketamine have not been tested in a large clinical trial.
Methods: The Prevention of Delirium and Complications
Associated with Surgical Treatments (PODCAST) study is
an international, multicentre, randomised controlled trial.
600 cardiac and major non-cardiac surgery patients will
be randomised to receive ketamine (0.5 or 1 mg/kg) or
placebo following anaesthetic induction and prior to
surgical incision. For the primary outcome, blinded
observers will assess delirium on the day of surgery
(postoperative day 0) and twice daily from postoperative
days 1–3 using the Confusion Assessment Method or the
Confusion Assessment Method for the ICU. For the
secondary outcomes, blinded observers will estimate
pain using the Behavioral Pain Scale or the Behavioral
Pain Scale for Non-Intubated Patients and patient self-
report.
Ethics and dissemination: The PODCAST trial has
been approved by the ethics boards of five participating
institutions; approval is ongoing at other sites.
Recruitment began in February 2014 and will continue
until the end of 2016. Dissemination plans include
presentations at scientific conferences, scientific
publications, stakeholder engagement and popular media.
Registration details: The study is registered at
clinicaltrials.gov, NCT01690988 (last updated March
2014). The PODCAST trial is being conducted under the
auspices of the Neurological Outcomes Network for
Surgery (NEURONS).
Trial registration number: NCT01690988 (last updated
December 2013).
INTRODUCTION
Background and rationale
Delirium
Postoperative delirium is one of the most
common complications of major surgery and
affects between 10% and 70% of all surgical
Strengths and limitations of this study
▪ Since the Prevention of Delirium and Complications
Associated with Surgical Treatments (PODCAST)
study is a multicentre international trial, the results
of the study will potentially be generalisable.
▪ This trial has a novel focus of assessing delirium
and pain concurrently. Results could reveal that
these two outcomes are potentially linked in the
postoperative setting.
▪ Investigators assessing for delirium have been
appropriately trained and will use reliable and
validated assessment tools.
▪ The Visual Analog Scale (VAS) is not a validated
pain assessment instrument in delirious patients.
In an attempt to mitigate this limitation, pain will
also be assessed observationally using the
Behavioral Pain Scale (BPS) and the Behavioral
Pain Scale—Non-Intubated (BPS-NI).
▪ Delirium is fluctuating in nature. Since patients
will be assessed at discrete time points, it is
possible that some episodes of delirium will not
be detected.
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1 The estimated
additional healthcare costs associated with delirium
exceed $60 000 per patient per year.
2 While causal rela-
tionships have not been established, delirium is asso-
ciated with increased morbidity and mortality, prolonged
length of hospital and intensive care unit (ICU) stay,
functional and cognitive decline with nursing home or
long-term care facility placement.
3–6 Furthermore, the
acute deterioration in cognition and psychomotor agita-
tion frequently seen with delirium is often distressing for
both patients and their families.
The diagnostic criteria for delirium have recently
been updated in the Diagnostic and Statistical Manual
of Mental Disorders, ﬁfth edition (DSM-V). Delirium is
an acute neurocognitive disorder characterised by a ﬂuc-
tuating level of consciousness with impairment of atten-
tion and cognition. In the postoperative context,
delirium typically manifests between 0 and 96 h follow-
ing surgical intervention. It is unclear why postoperative
delirium occurs so frequently. Age greater than 60, male
gender, history of dementia or depression, sensory
impairment and chronic medical illness are consistently
described as risk factors for delirium.
20 No effective
prophylactic or curative treatments for postoperative
delirium have been identiﬁed.
Ketamine and delirium
Ketamine is an anaesthetic agent that has been in
common use for more than 50 years. It has a wide
margin of safety, and as of 2005 had been studied in
over 12 000 operative and diagnostic procedures, involv-
ing over 10 000 patients from 105 separate studies (keta-
mine package insert 2005). There is a pharmacological
rationale for using ketamine as a preventative measure
against postoperative delirium based on its
N-methyl-D-aspartate (NMDA) antagonism.
21 Normally,
excitatory amino acids such as glutamate and aspartate
act as agonists at NMDA receptors, and in the setting of
surgery and inﬂammation, they might promote excito-
toxic injury and apoptosis.
21 As an NMDA antagonist,
ketamine has the potential to protect against such
neurological injury.
22 Ketamine has also been posited to
inhibit HCN1 receptors, which mediate the
hyperpolarisation-activated cation current.
23 Such inhib-
ition is pertinent to delirium because HCN1 channels
are important for regulating states of consciousness
24
and are upregulated by inﬂammation.
25 HCN1 receptors
are also thought to play a critical role in neuropathic
pain through inﬂammatory cascades.
26
On the basis of the pharmacological rationale for neu-
roprotection, a 58-patient randomised controlled trial
was conducted to determine whether ketamine might
prevent delirium after major cardiac surgery.
27 There
was a signiﬁcant reduction in postoperative delirium
from 31% to 3% with the administration of low-dose
ketamine (0.5 mg/kg) on induction of anaesthesia.
Although encouraging, this trial must be regarded as
preliminary owing to its small sample size and single-
centre design. Interestingly, the same investigators also
found that ketamine was associated with improved cogni-
tion beyond the immediate postoperative period.
28
Differences between the ketamine and placebo groups
were evident in tests of non-verbal memory, verbal
memory and executive function. The investigators found
that C reactive protein, a non-speciﬁci n ﬂammatory
marker, was similar at baseline in the ketamine and
placebo groups. On the ﬁrst postoperative day, C reactive
protein was elevated in both groups, but was signiﬁcantly
higher in the placebo group. The investigators hypothe-
sised that the neuroprotective effect of ketamine might
have been, in part, attributable to its anti-inﬂammatory
actions.
28 In support of the plausibility of this hypoth-
esis, ketamine use in another cardiac surgical population
was similarly shown to attenuate postoperative increases
in inﬂammatory markers.
29
An intraoperative subanaesthetic dose of ketamine is
appealing as a potential preventative intervention for
delirium, since it is inexpensive and has an excellent
safety proﬁle. A number of questions remain to be
answered regarding postoperative delirium. Despite the
fact that delirium is a common and serious postoperative
complication, intraoperative factors contributing to
pathogenesis have not been rigorously investigated, and
only a few small trials have been conducted that
examine interventions to decrease its incidence. It is
also currently unknown whether postoperative delirium
is preventable, particularly in patients with underlying
vulnerabilities. Importantly, ketamine in higher (anaes-
thetic) doses has become less popular over time owing
to its side effects, including hallucinations and emer-
gence reactions, especially in younger patients.
30 31 To
ensure treatment effectiveness, the preliminary results
identifying subanaesthetic doses of ketamine as a useful
preventative intervention for postoperative delirium
should therefore be conﬁrmed or refuted using a
large-scale, pragmatic, randomised controlled trial
design prior to routine adoption of low-dose ketamine
for this purpose.
Acute and persistent pain
Similar to delirium, both acute and persistent pain are
common postoperative complications, with a negative
impact on patients’ lives. The Joint Commission has
established the prevention of severe postoperative pain
as a benchmark of quality,
32 and adequate pain manage-
ment is increasingly viewed as a fundamental human
right.
33 34 Unfortunately, this standard of care has not
been attained to date; it has previously been estimated
that about a third of patients suffer severe acute postsur-
gical pain following major procedures.
35 Furthermore,
patients who have acute postoperative pain are more
likely to develop chronic pain, and the incidence of per-
sistent postoperative pain following major surgeries
remains between 5% and 30%.
36 As an antagonist at
NMDA and HCN1 receptors, ketamine has powerful
analgesic properties. A systematic review showed that a
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was associated with decreased visual analogue pain
scores up to 48 h postoperatively.
37 At 24 h postopera-
tively, ketamine was associated with an impressive 16 mg
decrease in total morphine consumption.
37
Furthermore, adverse effects such as hallucinations were
rarely reported when low-dose ketamine was adminis-
tered during general anaesthesia.
37 Consistent with
these ﬁndings, a Cochrane systematic review reported
that subanaesthetic doses of perioperative ketamine were
associated with decreased postoperative pain, decreased
morphine consumption and decreased nausea and
vomiting.
38 Adverse effects were mild or absent.
38 An
updated systematic review, which included 70 small
studies involving 4701 patients, recently conﬁrmed that,
in a dose-dependent manner, subanaesthetic intraopera-
tive ketamine was consistently associated with decreased
postoperative pain despite decreased opioid consump-
tion.
39 The more painful the surgical procedure, the
greater was the analgesic beneﬁt attributable to keta-
mine.
39 In keeping with the decreased opioid consump-
tion, postoperative nausea and vomiting were also less
frequent in patients who received ketamine. However,
patients who had been randomised to ketamine
reported hallucinations and nightmares more fre-
quently.
39 While efﬁcacy data, based on numerous small
studies, strongly suggest that supplementary ketamine
should be used to decrease pain and opioid usage post-
operatively, most practitioners have not incorporated
low-dose ketamine into their routine practice.
Preliminary data gathered from ﬁve institutions (see
below for details) involved in the Prevention of Delirium
and Complications Associated with Surgical Treatments
(PODCAST) trial suggest that despite their knowledge
regarding the analgesic and opioid-sparing effects, prac-
titioners do not administer low-dose ketamine for pain
because of concern for complications such as delirium.
Thus, effectiveness data regarding the relationship of
ketamine, delirium and pain are needed.
Although numerous small efﬁcacy studies have shown
that ketamine decreases acute postoperative pain, its
role in preventing persistent postoperative pain has not
been rigorously explored. Many causal mechanisms that
are thought to be implicated in persistent pain and a
single intraoperative intervention might not be sufﬁcient
to decrease its occurrence. However, there have been
encouraging ﬁndings about the potential of NMDA
antagonists to decrease postoperative persistent pain. In
the ENIGMA trial, patients were randomised to receive
intraoperative oxygen with either nitrogen or nitrous
oxide, which, like ketamine, is an NMDA antagonist.
The investigators found that among those patients who
received nitrous oxide, there was an absolute decrease in
the percentage of patients who experience persistent
pain (baseline incidence=15%) at 3 months postopera-
tively of 7% (95% CI 1.9% to 13.9%).
40 A randomised
study has examined the potential beneﬁcial effect of
intraoperative ketamine on persistent postoperative pain
among patients undergoing total hip replacement.
41
This trial found a reduction in the ketamine group from
Table 1 Incidence of delirium in major surgeries
Surgery
type Study Population
Delirium
rate (%)
Detection
method
Unselected Radtke et al
7 Recovery room after elective general
anaesthesia
9.9 Nu-DESC
Surgical ICU Pandharipande et al
8 Surgical ICU 73 CAM-ICU
Trauma ICU 67
Head and
neck
Weed et al
9 Major head and neck 17 Not stated
Cardiac Kazmierski et al
10 Cardiac surgery with CPB Age <60:
16.3
Age ≥60:
24.7
DSM-IV
Rudolph et al
11 Patients >60 undergoing elective or
urgent cardiac surgery
43 CAM
Saczynski et al
12 Patients >60 undergoing elective
coronary artery bypass grafting or valve
replacement surgery
46 CAM
Vascular Marcantonio et al,
13
Schneider et al,
14 Bohner et al
15
and Benoit et al
16
Abdominal aortic aneurysm repair 33–54 CAM or
DSM-IV
Schneider et al
14 and Bohner et al
15 Peripheral vascular 30–48 DSM-IV
Orthopaedic Fisher and Flowerdew
17 Patients >60 undergoing elective
orthopaedic procedures
17.5 CAM
Marcantonio et al
18 and Lee et al
19 Patients >65 undergoing emergent hip
fracture repair
30.2–41 CAM
CAM, Confusion Assessment Method; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition; ICU, intensive care unit;
Nu-DESC, The Nursing Delirium Screening Scale.
Avidan MS, et al. BMJ Open 2014;4:e005651. doi:10.1136/bmjopen-2014-005651 3
Open Access21% to 8% (reduction=13%; 95% CI 1.3% to 24.9%) in
patients experiencing persistent pain at 6 months after
their surgery.
41 The PODCAST study would demonstrate
whether a subanaesthetic dose of intraoperative keta-
mine is effective at preventing acute postoperative pain
in a real-world setting. If ketamine was shown to have a
substantial effect in decreasing acute postoperative pain,
a next step would be to investigate rigorously its impact
on persistent pain.
Current utilisation of low-dose ketamine
A survey of anaesthesia clinicians was conducted at ﬁve
of the institutions (Washington University in St Louis,
University of Michigan, University of Manitoba, Weill
Medical College of Cornell University and Medical
College of Wisconsin) participating in the PODCAST
clinical trial. In total, 270 clinicians responded to the
surveys; 18% (range among institutions 12–40%) of
respondents currently incorporate adjunctive subanaes-
thetic ketamine into their practice. Interestingly, 84% of
survey respondents believe that low-dose ketamine
decreases acute postoperative pain, 81% feel that it
decreases postoperative opioid consumption and 51%
believe that it decreases chronic postoperative pain.
However, the reason that a minority of practitioners are
currently administering adjunctive ketamine is probably
because many remain concerned about the neurological
side effects of even low-dose ketamine; 68% of respon-
dents expressed concern about hallucinations, 62%
about delirium and 55% about nightmares.
Potential impact of PODCAST
The PODCAST trial has a novel focus in that it is
assessing the impact of an intervention (subanaesthetic
racemic ketamine administration) on delirium and
pain, two adverse and potentially linked outcomes that
have not previously been jointly evaluated in a single
large clinical trial. Both delirium and pain are surpris-
ingly common acute postoperative complications with
major negative consequences for patients.
13 5
Currently, there are no ofﬁcial guidelines to screen
patients for delirium, and only a few preventive mea-
sures have been investigated, with disappointing
results. Since most patients with postoperative delirium
have a hypoactive phenotype, it is frequently missed in
clinical practice. As noted previously, postoperative
delirium is associated with increased intensive care
and hospital stay, with persistent cognitive decline and
with increased mortality. Thus, any intervention that
could decrease the incidence of postoperative delirium
would probably have major positive implications for
older patients undergoing surgical procedures. Unlike
delirium, acute postoperative pain is routinely assessed,
and the Joint Commission has prioritised the preven-
tion of severe postoperative pain as a universal goal.
Unfortunately, this objective has not been met, and
both severe acute pain and debilitating chronic pain
continue to afﬂict many surgical patients.
35 36 Of note,
both pain and its treatment with opioid analgesics can
be risk factors for delirium. Opioid analgesics are the
mainstay therapy for postoperative pain, but their
administration is curtailed in older patients particu-
larly for safety considerations regarding respiratory
depression, but also for concerns about causing sed-
ation and delirium.
Pragmatic trials are intended to generate evidence of
effectiveness of a test, treatment, procedure or health-
care service.
42 43 At present, there is a lack of pragmatic
trials for candidate interventions to prevent important
and common postoperative neurological and psychiatric
complications including delirium and pain. Ketamine is
a plausible prophylactic option for each of these neuro-
logical and psychiatric complications. The American
Society of Anesthesiologists has published Practice
Guidelines for the management of acute and chronic
pain, which, based on small efﬁcacy or observational
trials, include ketamine as a treatment option.
44 45
There are currently no guidelines for the prevention of
postoperative delirium. Thus, a multicentre pragmatic
trial comparing low-dose ketamine with placebo is
timely. It is important to emphasise that any one of
several potential results of the PODCAST trial will have
important and immediate positive implications for older
surgical patients. First, ketamine might decrease both
delirium and pain. This result would provide clear
support for a larger comparative effectiveness trial
testing ketamine as a prophylactic measure for both of
these outcomes. Second, ketamine might decrease pain
without increasing delirium. This result would provide
compelling data that encourage the use of ketamine to
prevent pain without concern for cognitive side effects
such as delirium. Third, ketamine might decrease delir-
ium and have no impact on pain. Although the lack of
effect on pain is unlikely, this result would also encour-
age further study of the use of prophylactic intraopera-
tive ketamine. However, low-dose ketamine may be
found to increase delirium, regardless of its impact on
pain. This result would suggest that the incorporation of
intraoperative ketamine into routine clinical practice for
older surgical patients is not warranted and would
negate the need for a larger pragmatic trial.
Furthermore, the PODCAST trial will help determine
ketamine dose-related effects by comparing two doses
(0.5 and 1 mg/kg) to placebo. As such, all of these
potential results of the PODCAST trial have the poten-
tial to impact clinical practice and will be generalisable
to all older surgical patients undergoing major surgical
procedures because of the permissive inclusion criteria
and the simplicity of intervention.
42
METHODS AND ANALYSIS
Study design
PODCAST is a prospective randomised controlled trial
that has been designed in accordance with the
CONSORT guidelines
46 and will evaluate whether a
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following induction of anaesthesia and before surgical
incision decreases the incidence or severity of post-
operative delirium and pain in a mixed elderly
(>60 years) surgical patient population. Patients will
undergo the standard preoperative anaesthesia assess-
ment. Follow-up information will be collected from the
medical chart for up to 5 years. The overall study design
is outlined in ﬁgure 1.
Eligibility criteria
Patients 60 years old and older, who are competent to
provide informed consent and who are undergoing major
open cardiac surgery (eg, coronary artery bypass graft,
valve replacement) or non-cardiac surgeries (eg, thoracic
surgery, major vascular surgery, intra-abdominal surgery,
open gynaecological surgery, open urological surgery,
major orthopaedic surgery, hepatobiliary surgery and
major ENT surgery) and receiving general anaesthesia,
will be eligible for inclusion. The exclusion criteria are
based on the contraindications to ketamine from the 2005
ketamine package insert. Patients with an allergy to keta-
mine and those in whom a signiﬁcant elevation of blood
pressure would constitute a serious hazard (eg, pheochro-
mocytoma, aortic dissection) will be excluded. We
shall also exclude patients with drug misuse history
(eg, ketamine, cocaine, heroin, amphetamine, metham-
phetamine, 3,4-methylenedioxy-N-methylamphetamine
(MDMA), phencyclidine, lysergic acid, mescaline, psilo-
cybin), patients taking antipsychotic medications (eg,
chlorpromazine, clozapine, olanzapine, risperidone, halo-
peridol, quetiapine, paliperidone, amisulpride, sertindole)
and patients with a weight outside the range 50–200 kg
(110–440 lbs). Patients will be enrolled either during a
preoperative clinic visit or in the hospital prior to surgery.
Baseline assessment
At the time of enrolment, patients will undergo the
same delirium and pain evaluation that will be used
postoperatively (see Outcomes section). Additionally,
patients will be screened for functional dependence
using the Barthel Index of Activities of Daily Living,
47
for depression using the Patient Health Questionnaire
(PHQ-8)
48 and for obstructive sleep apnoea using the
STOP-Bang criteria.
49 Patients will be asked if they have
a history of delirium, and if this presented after surgery.
They will also be asked about any falls they have experi-
enced in the 6 months prior to surgery. Comorbid con-
ditions, including the components of the Charlson
Comorbidity Index,
50 will be obtained by reviewing the
patients’ medical records. Any available preoperative
laboratory results, including electrolytes and blood
counts, will also be recorded.
Interventions
As this is a pragmatic trial, apart from administration of
the study drug (ketamine or normal saline), all decisions
about anaesthetic technique will be made by the
anaesthetic team assigned to each patient. The only
exception is that clinicians will be instructed not to
administer any ketamine other than the study drug. The
intention of this trial is to interfere as little as possible
with the usual process of care, which will increase the
applicability of the ﬁndings.
43 Following the induction
of general anaesthesia, an intravenous dose of 0.5 mg/
kg racemic ketamine, 1 mg/kg racemic ketamine or an
equivalent volume of normal saline will be injected via a
reliable (free-ﬂowing) central or peripheral intravenous
line. Clinicians will be blinded to the treatment arm of
the study. Anaesthetic factors such as the use of nitrous
oxide, protocols for pain prevention, use of neuraxial
anaesthesia, use of nerve blocks and other practices that
could potentially affect primary or secondary outcomes
will be assessed in a post hoc manner.
Outcomes
Primary outcomes
Trained members of the research team who are blinded
to the treatment arm of the study will assess patients for
delirium (primary outcome) using the Confusion
Assessment Method (CAM)
51 and the Confusion
Assessment Method for the Intensive Care Unit
(CAM-ICU)
52 53 for patients who are unable to speak
(eg, have a tracheal tube or tracheostomy) on the ICU.
These methods (the CAM and the CAM-ICU) have been
shown to be reliable and to have good agreement with
the DSM-IV criteria for delirium.
53–55 Delirium assess-
ments will be performed when patients can be aroused
sufﬁciently in order to be assessed for delirium
(Richmond Agitation and Sedation Score >−4). The ﬁrst
delirium assessment will be attempted if feasible on the
day of surgery in the afternoon/evening. Patients will
then be assessed for delirium twice daily (from post-
operative day 1 to postoperative day 3) in the morning
and in the afternoon/evening with at least 6 h between
assessments. Each patient will be assessed for delirium
up to seven times. At the Washington University site, the
patients’ family members will perform the Family
Confusion Assessment Method (FAM-CAM) separately
from the investigators performing their assessments.
56
Investigators and family members will be blinded to
each other’s assessments. The FAM-CAM has demon-
strated high sensitivity and speciﬁcity for detection of
delirium and good agreement with the CAM,
56 but has
not been speciﬁcally evaluated in the postoperative
setting. After the ﬁnal delirium assessment, patients will
complete the Delirium and Pain Self-Assessment
Questionnaire (see online supplementary appendix A).
Incident delirium subsequent to this period is unlikely
to be directly related to anaesthetic or other intraopera-
tive factors.
Secondary outcomes
Study team members blinded to the treatment group of
the patient will assess all secondary outcomes. Acute pain
(secondary outcome) will be assessed prior to surgery
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Scale (BPS)
57 or the Behavioral Pain Scale for the
Non-Intubated patient (BPS-NI)
58 and the 10 cm VAS
(Visual Analog Scale) at the same times as patients are
assessed for delirium. The BPS-NI has been shown to be
a valid and reliable tool for measuring pain in a predom-
inantly delirious patient population.
58 Interviewers will
rate the BPS or BPS-NI prior to asking the patient to
complete the VAS to prevent bias in the BPS and BPS-NI
assessments. The postoperative daily amount of opioids
and sedatives administered will be ascertained from the
patient’s electronic health record spanning the period
after surgery until the ﬁnal delirium assessment is com-
plete. After the ﬁnal delirium assessment, patients will
complete the Delirium and Pain Self-Assessment
Questionnaire (see online supplementary appendix A).
Postoperative nausea and vomiting (secondary outcome)
will be assessed at the same time points that patients are
Figure 1 Flow of participants.
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ity of their nausea and vomiting, if present, on a three-
point scale (mild, moderate, severe). Patients will be
questioned at each assessment about side effects, espe-
cially hallucinations and nightmares. Intensive care unit
and hospital length of stay will be obtained from the
patient’s medical record. At some of the participating
sites in the PODCAST trial, patients will receive a survey,
which will be sent by mail or email 1 month following
surgery. This survey will collect patient-reported out-
comes on depressive symptoms, affect, persistent pain,
functionality and quality of life. Depressive symptoms
will be assessed with the eight-item PHQ-8. Affect will be
assessed with two 10-item mood scales that comprise the
Positive and Negative Affect Schedule (PANAS) within
3–6 months postoperatively.
59 The same screens for
depressive symptoms and affect will also be conducted
in the hospital on postoperative day 3. Persistent pain
will be assessed with the Brief Pain Inventory Short
Form (BPI-SF). The Barthel Index will be used to report
functionality, and quality of life will be assessed from the
Veteran’s Rand-12 (VR-12) questionnaire.
Standardisation of training and outcomes assessment
All study team members who perform delirium assess-
ments will undergo a rigorous training process. For the
initial training, representatives from each study site partici-
pated in a full-day training programme led by SKI, the ori-
ginal creator of the CAM. Those who attended this initial
training will oversee the training of other team members
at their sites. Trainees must demonstrate competence at
both conducting CAM interviews and in scoring these
interviews. For the initial part of training, trainees must
conduct at least two satisfactory CAM interviews in the
presence of a trained team member. These interviews will
not be on patients enrolled in the PODCAST trial. To
establish their ability to score CAM interviews reliably, trai-
nees will accompany trained team members to conduct
CAM interviews. A trained member of the research team
will conduct each CAM interview for patients enrolled in
the PODCAST trial. The trainee will observe the interview,
but will score the CAM independently. The trainee must
agree with the trainer on the presence or absence of all 12
cognitive features assessed by the CAM on a minimum of
two delirious and two non-delirious patients. After
meeting the stipulations of training, the newly trained
team member will conduct their ﬁrst interview of a patient
enrolled into the PODCAST trial in the presence of a pre-
viously trained team member.
Assessment of the standardisation and reliability of delirium
assessments
After training, all PODCAST team members administer-
ing delirium assessments will be invited to participate in
a project to demonstrate the validity and reliability of
the CAM in our study population. Participants will view
and rate eight videos of standard interviews depicting
delirious and non-delirious patients. They will also
independently score the CAM for each scenario.
Demographic information, level of education, level of
clinical experience and primary language will also be
collected from all participants. Data will be de-identiﬁed.
All scores and data will be submitted to the lead site,
Washington University. The group’s scores will then be
compared to determine the reliability of delirium assess-
ments across sites. Additionally, the group’s scores will
be compared with a set of ‘gold standard’ scores for the
videos (determined by SKI’s team). This comparison is
intended to demonstrate the validity of the CAM in our
study setting. Overall, the goal of the project is to dem-
onstrate standardisation of the delirium outcome across
all study sites.
Sample size
On the basis of the published delirium incidences in the
scientiﬁc literature (table 1), we estimate conservatively
that the incidence of postoperative delirium in a mixed
major surgical population of older patients will be
between 20% and 25%. Based on data from a substudy
of the BAG-RECALL trial that we have recently com-
pleted, the incidence of delirium among patients admit-
ted to our cardiothoracic intensive care unit at
Barnes-Jewish Hospital is 25% within three postoperative
days. Hudetz et al
27 found that ketamine was associated
with a 28% (95% CI 8% to 46%) absolute risk reduction
in delirium (from a baseline incidence of 31%). A 28%
reduction is likely to be an overoptimistic effect size for
designing a pragmatic study; 10% is more realistic as the
most optimistic effect size and remains consistent with
the CI for the effect size found by Hudetz et al.
27
Assuming a two-sided type I error rate of 5%, a sample
size of 600 will give greater than 80% power to detect a
decrease in the incidence of delirium from 25% to 15%
with ketamine. On the other hand, we consider the
minimum clinically important difference (MCID) or
effect size to be 2%, which corresponds to a number
needed to treat 50 surgical patients to prevent one
episode of delirium. The rationale for the low MCID is
that delirium is a serious postoperative complication that
is associated with increased mortality and the proposed
intervention (low-dose ketamine) is safe, inexpensive
and not likely to have adverse effects.
There are two speciﬁc issues to clarify in this study:
(1) the likely effect size with ketamine and (2) the
optimal ketamine dose. Ketamine might increase delir-
ium, decrease delirium or have no impact on delirium.
If ketamine increases delirium, it is more likely to
increase delirium at a higher dose (1 mg/kg). If keta-
mine decreases delirium, it might have a dose–response
effect—less delirium at the higher ketamine dose
(1 mg/kg). We anticipate that ketamine will decrease
pain in a dose-dependent manner—1 mg/kg will be
superior to 0.5 mg/kg. Accrual of 200 patients to each
dose of ketamine along with a placebo arm will allow a
more robust assessment of the dose–response efﬁcacy
for postoperative analgesia than previous studies with
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might have more side effects. As such, this trial might
inform whether the higher ketamine dose can be used,
in view of its possibly superior analgesia, with a potential
beneﬁt in relation to delirium and without excessive side
effects. The dosage determination going forward will
depend on the observed incidence of delirium with
each dose, analgesia efﬁcacy with each dose and side
effect proﬁle with each dose. The proposed design for
the study is shown in table 2.
With this approach, we believe that this study will
clearly inform whether it is indicated, both in terms of
efﬁcacy as well as feasibility, to pursue a larger study.
The purpose of the larger study (PODCAST2) will be to
determine deﬁnitively whether ketamine is associated
with a reduction in delirium (and pain) in high-risk
older surgical patients, without incurring an increase in
side effects. As the main effect evaluated will be to deter-
mine whether ketamine decreases delirium, table 3 pro-
vides a useful guide for the potential ﬁndings of the
current study with their implications.
Recruitment
This clinical trial will be conducted at Washington
University in St Louis and other sites. Our research team
has conducted large randomised controlled trials, which
enrolled (approximately) 2000 patients over 14 months
in the B-unaware trial,
60 6000 patients over 26 months in
the BAG-RECALL trial
59 and 22 000 patients over
24 months in the Michigan Awareness Control Study.
61
On the basis of the inclusion criteria and the number of
eligible surgical patients, we estimate that 1 year will be
sufﬁcient for patient enrolment to the proposed trial,
and a further 1 year for data analysis.
Allocation
Participants will be block randomised by the hospital
pharmacy departments in groups of 15 (1:1:1 ratio—
0.5 mg/kg ketamine: 1 mg/kg ketamine: placebo), strati-
ﬁed by site, in order to keep the randomisation
balanced and the groups more homogeneous. The
outcome of this random assignment will be concealed
from the study team, and all study participants and trial
staff will be blinded to the randomisation. Codes will be
held by the hospital pharmacies and they will dispense
medication. Randomisation codes will remain concealed
until the primary analysis is completed. Prepared syr-
inges of either placebo or ketamine will be directly deliv-
ered to the operating room in which surgery of the
consenting patient will take place as soon as the research
team informs the pharmacy about the patient going to
the operating room for surgery.
Data analysis and management
Data analysis for this investigation will require compari-
sons of patient outcomes (eg, delirium, pain, length of
stay, adverse events) in the three study groups to assess
for signiﬁcant differences among ketamine doses
(placebo, 0.5 mg/kg and 1 mg/kg). For proportions
and categorical outcomes, such as incident delirium, we
will use the χ
2 test (or Fisher’s exact test in the case of
sparse data) to compare proportions across the three
groups and the Cochran-Armitage test to test for dose–
response trends. For continuous outcomes, such as
visual analogue pain scores and opioid consumption, we
will use repeated-measures analysis of variance tests to
detect the main effects. The Tukey post hoc test will also
be run on all signiﬁcant interactions to determine differ-
ences between individual and combined groups (eg,
placebo vs combined ketamine groups; 0.5 vs 1 mg/kg
ketamine). For multivariate analyses, we will apply the
Cox proportional hazards model for recurrent events to
investigate the effects of low doses of intraoperative keta-
mine on delirium by comparing its occurrence and
timing across the study groups. We will also model the
number of postoperative delirium incidents using a
Poisson hurdle regression to ﬁnd out the difference in
the proportion of patients with and without delirium,
and for those who experience delirium, the difference
in its recurrence. Both models (Cox proportional
hazards and hurdle model) will account for differences
in ketamine effectiveness in cardiac versus non-cardiac
surgery by including interaction terms for ketamine
dose and cardiac surgery status, while adjusting for other
inﬂuential variables. We will also use mixed-effects
regression models to assess differences among subgroups
in continuous outcome variables over time (eg, post-
operative pain scores and opioid consumption). These
models will likewise account for interactions between
ketamine dose and cardiac surgery status. All statistical
testing will be two-sided, and p values <0.05 will be
regarded as signiﬁcant. No interim analyses are
planned. Appropriate adjustment will be made for mul-
tiple analyses.
The Division of Biostatistics Informatics Core at
Washington University will be used as a central location
for data processing and management. Washington
University belongs to a consortium of institutional part-
ners that works to maintain a software toolset and work-
ﬂow methodology for electronic collection and
management of research and clinical trial data. REDCap
(Research Electronic Data Capture) data collection pro-
jects rely on a thorough study-speciﬁc data dictionary
deﬁned in an iterative self-documenting process by all
members of the research team with planning assistance
from the Division of Biostatistics Informatics Core. The
iterative development and testing process results in a
Table 2 Patient allocation
Group N
Placebo 200 patients
Ketamine low dose (0.5 mg/kg) 200 patients
Ketamine moderate dose (1 mg/kg) 200 patients
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studies. REDCap servers are securely housed in an
on-site limited access data centre managed by the
Division of Biostatistics at Washington University. All
web-based information transmission is encrypted. The
data are all stored on a private ﬁrewall protected
network. All users are given individual user IDs and pass-
words and their access is restricted on a role-speciﬁc
basis. REDCap was developed speciﬁcally around
HIPAA-Security guidelines and is implemented and
maintained according to the Washington University
guidelines. REDCap currently supports >500 academic/
non-proﬁt consortium partners on six continents and
38 800 research end users.
62
Monitoring
The research team will monitor the study for adverse
events. All serious adverse events will be reported to the
Institutional Review Board (IRB) according to the IRB sti-
pulations. The monitoring plan for this study is appropri-
ate for the planned pragmatic trial. As an anaesthetic
drug, ketamine has an excellent safety proﬁle and record.
In particular, low-dose ketamine (0.5 or 1 mg/kg) adminis-
tered prior to surgical incision is unlikely to be associated
with major adverse events, and even minor side effects
manifesting after induction of anaesthesia and the start of
surgery are improbable.
37 38 63
The PODCAST trial will have an appropriate data and
safety monitoring plan for a low-risk clinical trial. There
will be a charter to guide the functions of the Data
Safety and Monitoring Board (DSMB), and the DSMB
will produce reports in accordance with the NIH guide-
lines. The DSMB will provide independent oversight of
the PODCAST trial and will review the general conduct
of the trial as well as study data for participant safety.
64
The DSMB will comprise independent, multidisciplinary
experts who will make recommendations regarding the
continuation, modiﬁcation or termination of the trial.
65
The members will have the requisite expertise to
examine accumulating data, to protect the integrity of
the clinical experiments in which the patients have con-
sented to participate and to assure the regulatory bodies
and the public (and possibly funding agencies) that con-
ﬂicts of interest do not compromise either patient safety
or trial integrity.
66 There will be no prespeciﬁed interim
analysis given the size of this study; frequent analyses
might increase the likelihood of bias.
64 There will be a
provision for early stoppage for safety concerns, but not
for efﬁcacy or for futility.
64 Trials that stop early for
beneﬁt show implausibly large treatment effects, particu-
larly when the number of events is small.
67 Truncated
trials have been associated with greater effect sizes than
trials not stopped early, independent of the presence of
statistical stopping rules.
68
All members of the DSMB will be at the Washington
University site. Local investigators at all participating
sites will report serious adverse events, or unanticipated
problems involving risks to participants or others, to
their IRB and to the principal investigator (PI) of the
study at Washington University. If such problems are
considered to be related to the trial, then they will also
be reported to IRBs at other participating sites and to
the chairperson of the DSMB. The members of the
DSMB will have no direct involvement in the conduct of
the PODCAST trial. Neither will they have ﬁnancial, pro-
prietary or professional conﬂicts of interest, which may
affect the impartial, independent decision-making
responsibilities of the DSMB.
64 65 Letters of invitation to
prospective DSMB members will include the following:
“Acceptance of this invitation to serve on the PODCAST
DSMB conﬁrms that I do not have any ﬁnancial or other
interest with any of the collaborating or competing
pharmaceutical ﬁrms or other organizations involved in
the study that constitute a potential conﬂict of interest.”
Table 3 Potential findings of PODCAST
Delirium incidence in placebo
groups (N=200) (%)
Delirium incidence in ketamine
groups (N=400) (%)
Effect size (reduction in
delirium with ketamine) (%)
95% CI for
effect size (%)
25 (N=50) 25 (N=100) 0 −7.6 to 7.1
Implication: consider pursuing a larger study only if pain is decreased in ketamine groups, and there is no increase in side
effects
25 (N=50) 22.5 (N=90) 2.5 −4.5 to 10.0
Implication: although the point estimate is >2% (MCID), a 9500 patient study would be required to clarify more precisely the
effectiveness of ketamine in preventing delirium. Other outcomes in the study (eg, pain reduction and side effects) would
inform the approach
25 (N=50) 20 (N=80) 5 −1.9 to 12.4
Implication: pursue a larger study with approximately 2500 patients to clarify more precisely the effect of ketamine on
preventing delirium
25 (N=50) 17.5 (N=70) 7.5 0.7 to 14.8
Implication: pursue a larger study (approximately 1200 patients) to clarify whether effect size >2% (MCID) and to define it
more precisely
25 15 10 3.3 to 17.1
Implication: for a main effect, a lower bound of CI >2% (MCID). Ketamine’s benefit in decreasing delirium is very likely, but a
larger study (approximately 1200 patients) would define its effect more precisely
PODCAST, Prevention of Delirium and Complications Associated with Surgical Treatments; MCID, minimum clinically important difference.
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Certiﬁcation to conﬁrm that no conﬂict exists. There
will be between three and eight people on the DSMB, in
order to optimise performance.
69 The DSMB will be
advisory rather than executive on the basis that it is the
PODCAST trial investigators who are ultimately respon-
sible for the conduct of the trial.
69
The risks associated with this study are low. There is a rare
risk of breach of conﬁdentiality. In contrast to other anaes-
thetics, protective reﬂexes such as coughing and swallowing
are maintained with low-dose ketamine. The 2005 package
insert for ketamine reports the induction dose for anaesthe-
sia as follows: the initial dose of ketamine administered intra-
venously may range from 1 to 4.5 mg/kg. The average
amount required to produce 5–10 min of surgical anaesthe-
sia has been 2 mg/kg. The short-term side effects of keta-
mine at higher doses (>1–2 mg/kg) than the dosages
proposed for this study (0.5 or 1 mg/kg) include tachycar-
dia, nystagmus, hypersalivation, euphoria, emergence reac-
tions, hallucinations and nightmares.
70 It is possible, but
very unlikely, that low-dose ketamine (0.5 or 1 mg/kg) admi-
nistered just after induction of anaesthesia or administration
of sedative medications will cause these side effects.
37 38 63
Emergence reactions, hallucinations and nightmares are
more common in younger patients receiving ketamine. In
published studies on low-dose ketamine (0.25–1m g / k g )
administered during general anaesthesia, side effects have
generally not been found.
37 The main side effects that
might occur are nightmares and hallucinations. Other
neuropsychiatric side effects might occur, most likely within
the ﬁrst 24 h after surgery, and will be determined from
patient interviews. The incidence of these side effects in this
patient population is currently unknown, and thus side
effects will be reported separately and jointly. Meta-analysis
suggests that ketamine might be associated with an increase
in neurological and psychiatric side effects from approxi-
mately 5% to 7.5%. This study will be >80% powered to
detect an increase in side effects from 5% to 12% and 20%
powered to detect an increase in side effects from approxi-
mately 5% to 7.5%. As part of the informed consent process
for this study, patients will be informed of the rare risks and
will be asked about them after their surgery. In the unlikely
event that serious side effects occur, they will be documen-
ted and also reported to the human research protection
ofﬁce and to the study’s DSMB. Participants will not incur
any study-related expenses, and nor will they be ﬁnancially
compensated for theirp a r t i c i p a t i o n .
Ethics and dissemination
Ethics approval and consent
The PODCAST trial has been approved by the IRBs of
the PIs’ home institutions (Washington University, St
Louis and University of Michigan, Ann Arbor). IRB
approval has also been obtained at some of the partici-
pating sites (Postgraduate Institute of Medical Education
and Research, Chandigarh, India; University of
Manitoba, Winnipeg, Canada; Weill Medical College,
Cornell University, New York City; Medical College of
Wisconsin, Milwaukee) and is ongoing at other sites.
Recruitment began in February 2014 and will continue
until the end of 2016. Potential participants will be
approached for enrolment by a member of the research
team who will explain the purpose of the study and
written informed consent will be obtained for all partici-
pants. Patients may choose not to participate in this
study and there will be no penalty in terms of the care
that they receive.
Confidentiality
Necessary protected health information will only be
shared with members of the research team. To help
protect conﬁdentiality, research charts will be stored in a
locked cabinet inside the locked research ofﬁce.
Electronic data and demographic information will also
be kept in a password-protected electronic database
stored on the departmental network drive and only
accessible via password-protected departmental compu-
ters. A member of the research team will enter this
information. Code numbers, rather than names, will
appear on any data and documents used for evaluation
or statistical analyses.
Dissemination
Dissemination plans include presentations at local,
national and international scientiﬁc conferences. There
are no publication restrictions and no professional
writers will be involved in the generation of the
manuscript.
CONCLUSIONS
In the next four decades, the US population over the
age of 60 is predicted to double to more than 80 million
individuals. The ageing population often requires
surgery, which can be frequently complicated by post-
operative pain and delirium. Delirium is deﬁned as an
acute brain dysfunction that presents as ﬂuctuating
levels of inattention and disordered thinking, and has
been reported to affect up to 70% of surgical patients
older than 60. Likewise, severe postoperative pain con-
tinues to affect a large proportion of surgical patients,
especially the elderly, and is another major contributor
to delirium. Unfortunately, opioid medications, the
current standard for analgesia, can themselves lead to
delirium and other adverse consequences. Clinicians
therefore face the paradox that both pain and the main-
stay treatment of pain can lead to delirium. Although
causal relationships have not been established, post-
operative delirium is associated with increased ICU and
hospital stay, persistent cognitive decline and increased
mortality rate. What is needed is a therapeutic interven-
tion that can both attenuate pain and decrease the
occurrence of delirium. Mounting evidence suggests
that the intraoperative administration of low-dose
(ie, subanaesthetic) ketamine, an anaesthetic drug that
has been in common use for 50 years, prevents delirium,
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Open Accesslessens the severity of postoperative pain, and has an
opioid-sparing effect. These multiple beneﬁcial effects
have been attributed to ketamine’s anti-inﬂammatory
and antiexcitotoxic actions. Despite these beneﬁts,
low-dose intraoperative ketamine currently does not
enjoy widespread adoption, primarily because clinicians
are concerned that the psychoactive properties of keta-
mine might compromise postoperative cognition. The
PODCAST randomised controlled trial intends to
address a gap in the ﬁeld through an international mul-
ticentre study that tests the effectiveness of ketamine in
reducing both delirium and pain in surgical patients
older than 60.
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